Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns DTC Genetic Test Firms

This article was originally published in The Tan Sheet

Executive Summary

The warning letters are the first FDA sent since it carved out a de novo risk category for DTC carrier screening tests, clearing the path for 23andMe Inc. to relaunch its Personal Genome Service in October.

Advertisement

Related Content

Personal Genome Service For Carrier Screening Emerges From 23andMe Work With FDA
FDA, 23andMe Open Up Market Pathway For DTC Genetics

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS108022

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel